WOODSTOCK, Ga., January 20, 2022–(Business WIRE)–Sonoma Prescription drugs, Inc. (Nasdaq: SNOA), a international health care chief creating and producing patented Microcyn® technologies-based mostly stabilized hypochlorous acid (HOCl) items for a vast selection of purposes, which include wound, eye, oral and nasal care, disinfectant use and dermatological situations, currently announced that it has extra Salus Health-related as an more distribution lover in the United States for dental treatment and expanded its oral and dental treatment traces to China through a partnership deal with Anlicare Global.
Sonoma entered into a non-special arrangement with Salus Professional medical to distribute Endocyn® root canal irrigant via their existing dental channels. In addition, Salus Healthcare will expand on their slicing-edge dermatology choices with Sonoma’s Microcyn® RX and Regenacyn® In addition merchandise and have non-special distribution legal rights for Microcyn® wound care goods.
“We believe that Endocyn root canal irrigant will be a wonderful addition to our solution portfolio at Salus Health-related. The two Endocyn and the Microcyn line of goods suit with our system of staying dedicated to providing benefit to the U.S. health care system although combining quality and economic system,” claimed Hernan Alvarez, President of Salus Professional medical.
Moreover, on January 18, 2022, Sonoma and Anlicare agreed to cooperate to comprehensive the regulatory get the job done necessary to get licenses in China to distribute Sonoma’s Microcyn® technology-primarily based dental and oral goods. Anlicare will bear the regulatory costs and in return, Sonoma agreed to grant Anlicare exceptional legal rights for providing and distributing oral and dental care products and solutions in China.
“We see the strength of Sonoma’s Microcyn engineering in the prevention of an infection and reduction of bacteria and microorganisms and consider Sonoma’s Microcyn technological know-how will be useful for dentistry and common oral treatment for each professional and purchaser use,” commented Sherwin Hu, CEO at Anlicare International.
“We are pleased to insert Salus Medical and Anlicare to our expanding network of distributors for our oral and dental products and solutions, and we keep on to seek out distribution partners for our proprietary Microcyn engineering that is genuinely remarkable in phrases of antimicrobial impression, shelf balance and security,” said Bruce Thornton, COO of Sonoma Pharmaceuticals.
About Salus Clinical
Considering the fact that 2012, Salus Clinical is a national wholesale distributor centered in Phoenix, Arizona. As generic wholesaler or generic pharmaceutical distributor, Salus Health care has been centered on delivering financial state and value to its clientele. Due to its target on client’s wants, Salus Health-related has seasoned remarkable development within just its small historical past. As Salus Health care has produced above the several years, it has shaped strategic relationships with a large range of suppliers nationwide, enabling Salus Health-related to source a range of very low-cost nevertheless higher-excellent products. By presenting a wide portfolio of goods, Salus Health-related is capable to assistance various health-related facilities and providers within just the healthcare continuum which include pharmacies, clinics, surgical treatment centers, and hospitals.
About Anlicare International
Started in 2012, the founders and management workforce of Anlicare Worldwide appear from major Chinese pharmaceutical organizations with a long time of valuable encounter of the Chinese pharmaceutical and professional medical gadget marketplaces. Anlicare has been doing work closely with leading intercontinental health-related firms and best healthcare scientific groups in China in many medical fields to provide and commercialize impressive professional medical gadgets and consumables into the Chinese industry.
About Sonoma Prescribed drugs, Inc.
Sonoma Pharmaceuticals is a world healthcare chief for establishing and making stabilized hypochlorous acid (HOCl) products for a broad selection of apps, which include wound care, animal health care, eye care, nasal treatment, oral care, disinfectant use and dermatological disorders. The company’s products and solutions lessen bacterial infections, itch, soreness, scarring and dangerous inflammatory responses in a harmless and effective method. In-vitro and medical reports of hypochlorous acid (HOCl) demonstrate it to have extraordinary antipruritic, antimicrobial, antiviral and anti-inflammatory attributes. Sonoma’s stabilized HOCl straight away relieves itch and suffering, kills pathogens and breaks down biofilm, does not sting or irritate pores and skin and oxygenates the cells in the spot treated helping the physique in its normal therapeutic system. The company’s solutions are bought both specifically or by way of companions in 54 international locations worldwide and the firm actively seeks new distribution companions. The company’s principal place of work is in Woodstock, Ga, with production functions in Latin The united states. European promoting and revenue are headquartered in Roermond, Netherlands. Extra info can be uncovered at www.sonomapharma.com. For partnership possibilities, please make contact with [email protected]
Other than for historic information herein, issues established forth in this press release are ahead-looking in the indicating of the “safe harbor” provisions of the Non-public Securities Litigation Reform Act of 1995, like statements about the industrial and technological innovation development and long term money overall performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “business”). These ahead-searching statements are identified by the use of words and phrases these types of as “carry on,” “establish” and “develop,” among others. Ahead-hunting statements in this push launch are issue to sure hazards and uncertainties inherent in the company’s company that could bring about real outcomes to vary, together with such dangers that regulatory medical and guideline developments may possibly transform, scientific knowledge might not be sufficient to meet regulatory specifications or receipt of demanded regulatory clearances or approvals, clinical effects may well not be replicated in true affected individual settings, security presented by the company’s patents and patent apps might be challenged, invalidated or circumvented by its rivals, the readily available industry for the company’s products and solutions will not be as significant as expected, the company’s items will not be in a position to penetrate one particular or far more focused markets, revenues will not be ample to meet the company’s hard cash demands, fund more enhancement, as nicely as uncertainties relative to the COVID-19 pandemic and economic enhancement, various solution formulations and a multitude of assorted regulatory and advertising requirements in unique countries and municipalities, and other challenges in-depth from time to time in the company’s filings with the Securities and Exchange Commission. The firm disclaims any obligation to update these ahead-seeking statements, apart from as needed by regulation.
Sonoma Pharmaceuticals™, Microcyn®, Endocyn® and Regenacyn® are emblems or registered logos of Sonoma Pharmaceuticals, Inc. All other logos and services marks are the assets of their respective homeowners.
Check out resource model on businesswire.com: https://www.businesswire.com/information/residence/20220120006023/en/
Media and Trader Make contact with:
Sonoma Pharmaceuticals, Inc.